RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets Hard-to-Cure leukemia in early trial
Disease control OngoingThis early-stage study tests whether adding immune-boosting drugs (nivolumab and ipilimumab) to blinatumomab can help people with a severe form of B-cell leukemia that has returned or not responded to treatment. The main goals are to find safe doses and understand side effects. A…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:42 UTC
-
Immunotherapy shows promise in battling relapsed childhood leukemia
Disease control OngoingThis study compares a targeted immunotherapy drug, blinatumomab, with standard chemotherapy in 669 children and young adults whose B-cell acute lymphoblastic leukemia has returned after initial treatment. The goal is to see if blinatumomab can keep the cancer away longer and impr…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New cocktail of drugs shows promise against tough leukemia
Disease control OngoingThis early-phase study tests a combination of drugs, including venetoclax, for adults with a specific type of leukemia (Ph+ ALL) that is either newly diagnosed or has returned. The goal is to find the safest dose and see how well the treatment works. About 20 participants will re…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New targeted therapy shows promise for Hard-to-Treat leukemia
Disease control OngoingThis study tests a drug called inotuzumab ozogamicin in 40 adults with B-cell acute lymphoblastic leukemia who still have tiny amounts of cancer cells after treatment. The drug works like a smart bomb, attaching to a protein on cancer cells and killing them. The goal is to see if…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:18 UTC
-
Promising combo targets Hard-to-Treat leukemia
Disease control OngoingThis study tests a new combination of two drugs—venetoclax and vincristine—in adults with acute lymphoblastic leukemia (ALL) that has returned or not responded to prior therapy. The goal is to find the safest dose and see if the combination can help more patients achieve remissio…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC